Actively Recruiting
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
Led by Mayo Clinic · Updated on 2026-03-31
66
Participants Needed
1
Research Sites
158 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.
CONDITIONS
Official Title
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Post-menopausal women with hormone receptor positive breast cancer, ductal carcinoma in situ (DCIS), or other high risk breast conditions
- Post-menopause defined as 12 months of amenorrhea or bilateral salpingo-oophorectomy
- Women planning to start or within 6 months of starting aromatase inhibitor treatment
- Women starting tamoxifen treatment (comparative group)
- Healthy post-menopausal women
You will not qualify if you...
- Established diagnosis of diabetes
- Use of medications that affect glucose metabolism
- Screening fasting glucose ≥ 126 mg/dl, or HbA1c ≥ 6.5%
- History of upper gastrointestinal surgery causing malabsorption or altered gastric emptying, such as bariatric surgery or fundoplication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here